



## Texas Tech University HSC Researchers Patent Early Detectable Blood-Based Biomarker for Alzheimer's Disease



A United States patent was recently awarded to P. Hemachandra Reddy, Ph.D., and Subodh Kumar, Ph.D., from the Department of Internal Medicine at the Texas Tech University Health Sciences Center School of Medicine.

The patent, "MicroRNA-455-3p as a Peripheral Biomarker for Alzheimer's Disease," focuses on the development of a novel blood-based biomarker for the early detection of Alzheimer's disease.

[Read full press release](#)

## AskBio & ReCode Therapeutics Exploring Strategic Collaboration in Single Vector Gene Editing Platform



Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics.

Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.

[Read full press release](#)

## Caris Life Sciences Raises \$400 Million



Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the company has closed a senior secured term loan providing up to \$400 million in capital from OrbiMed and Braidwell. With this funding, Caris has raised approximately \$1.7 billion in capital since 2018.

[Read full press release](#)

## Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184's Phase 1 Clinical Trial



Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern's clinical development plans for its LP-184 program.

LP-184 has shown nanomolar potency across a range of cancers including several solid tumors and multiple adult and pediatric central nervous system (CNS) cancers. The FDA feedback clears Lantern's path for an IND submission and the targeted initiation of a first-in-human clinical trial in Q2 2023.

[Read full press release](#)

## Congratulations To Our Members For Winning The Innovation Awards 2023



D CEO and Dallas Innovates revealed the winners of The Innovation Awards 2023 at a private event in the Dallas Design District. The program honors leaders, entrepreneurs, and trailblazers who are paving the way forward for innovation in North Texas.

### Innovation Advocate or Accelerator Leader of the Year Winner



Hubert Zajicek has built a sustainable business model that relies entirely on sponsors, private angel investors, and family office funds to fuel his organization, rather than a governing board or entity. For the past 10 years, Zajicek has guided the accelerator in mentoring entrepreneurs and investing in 99 startups that have raised more than a quarter of a billion dollars.

### Innovation in Biotechnology Winner



Caris Life Sciences has created a revolutionary new standard for cancer testing and monitoring, using liquid biopsies to test a person's blood and be able to diagnose and determine the proper treatment therapy for people with cancer, avoiding invasive,

inaccurate, and time-consuming tests used in many other cancer diagnoses.

## Innovation in Healthcare Winner



Mark Cuban Cost Plus Drug Company is working on a Dallas factory that will complete the final step in the manufacturing process to deliver drugs to patients—some of whom may not get their medicine otherwise because they suffer from conditions with patient pools too small to be profitable for larger drug companies to produce them.

[Read full press release](#)

## EisnerAmper Named a 2022 "Top 10 Employee Benefits Service Company"



HR Tech Outlook magazine has named EisnerAmper Wealth Management and Corporate Benefits as one of its "Top 10 Employee Benefits Service Companies" for 2022.

"We're glad to feature EisnerAmper as one of 2022's Top 10 Employee Benefits Service Companies. The company's goal is to help those we serve to best understand complex ideas and concepts so clients can benefit by applying what they communicate to help clients achieve their best financial life," said Hanna Wilson, Managing Editor of HR Tech Outlook Magazine.

[Read full press release](#)

## Texas A&M Fort Worth Moving Quickly Towards Construction of Urban Research Campus



TEXAS A&M  
FORT WORTH

The city's new \$350 million downtown Texas A&M University campus received its official new name — Texas A&M-Fort Worth. The campus also has its own team of architects and construction managers who will start work on the Law & Education building this summer. The campus will be a hub of education and innovation, including programs focused on engineering, business and law.

Tarleton State University will also find an additional home at the downtown campus. Tarleton President James Hurley said the expansion will allow the university to launch a biotechnology program to be housed at the campus.

[Read full press release](#)

# What Will Innovation Look Like in Fort Worth in 2023?



The Fort Worth Report spoke with innovators and new technology advocates to reflect on the previous year, and what new innovations might be on the horizon in 2023.

Electric and hydrogen-powered vehicles. Artificial intelligence. Breakthroughs in Alzheimer's treatment. These are a few trends Fort Worth residents might see in 2023, according to city and company officials focused on innovation.

[Read full press release](#)

## Investing In The Next Generation of Innovators



The North Texas Biotech Workforce Fund, enables persistence and improved graduation rates for students in pursuit of their biotech degree helping to develop the biotech talent pipeline in North Texas. The Last Mile Education Fund is investing in increasing access to biotech careers for striving low-income North Texas students.

Students with financial need are eligible to apply. Applicants must be enrolled in a 2 or 4 year, eligible biotech program in North Texas.

[Apply now](#)

## Call for Abstracts - 2023 MHSRS

Submission Deadline ends on February 19, 2023



Submit your abstracts to the The Military Health System Research Symposium (MHSRS) before February 19, 2023. Abstracts submitted to the MHSRS should represent original, unpublished work (not on-line, not in print). Abstracts can be submitted to MHSRS as well as to professional scientific society meetings. However, if the abstract is submitted to MHSRS and other military-related/DoD meetings and accepted, the submitter needs to decide which meeting to present at. Abstracts presented at other military-related or DoD meetings are ineligible for presentation at the MHSRS, unless there are extenuating

circumstances.

Apply now

## FDA No Longer Needs To Require Animal Tests Before Human Drug Trials

### Science

New medicines need not be tested in animals to receive U.S. Food and Drug Administration (FDA) approval, according to legislation signed by President Joe Biden in late December 2022. The change—long sought by animal welfare organizations—could signal a major shift away from animal use after more than 80 years of drug safety regulation.

In order for a drug to be approved in the United States, FDA typically requires toxicity tests on one rodent species such as a mouse or rat and one nonrodent species such as a monkey or dog. Companies use tens of thousands of animals for such tests each year. Yet more than nine in 10 drugs that enter human clinical trials fail because they are unsafe or ineffective, providing grist to those who argue that animal experiments are a waste of time, money, and lives.

Read full press release

## Join BioNTX for Deep Dive into FDA Authorization and IND Applications

BIONTX

### REGULATORY 201

Is your goal filing an IND?

Join Us!

Dallas

January 25



PEGASUS PARK

Fort Worth

January 26

TECHFVW



Trey Putnam, PhD, RAC

Vice President,  
Regulatory Affairs & Quality Assurance  
Osteal Therapeutics

Join BioNTX for our Regulatory 201 educational breakfast meeting and hear from our guest speaker Dr. Trey Putnam at Osteal Therapeutics, learn what an Investigational New Drug (IND) Application is, how the IND process works, FDA's expectations for an IND and

what to do when something goes wrong.

Register now - Dallas

Register now - Fort Worth

## 2023 Career EXPO - February 10th Meet PhD and Post Doc Candidates

# BIONTX



Join BioNTX at our Career Expo on February 10th! Your company will have the opportunity to recruit and network with top local talent and provide them with information about your open positions, review their resumes, and create brand awareness.

Register now

## Upcoming Events & Opportunities in North Texas



### How to Optimize Your R&D Tax Credits with ADP

*Biotechnology Innovation Organization*

Join BIO to learn about eligible tax credit activities, where state R&D benefits may exist, and how to maximize the new ADP tax credit offering now available to BioNTX members.

**January 24, 2023**

[Learn more here](#)



### Meeting with Texas Legislators *Healthcare Think Tank*

Join Healthcare Think Tank to listen to Texas legislators discuss top healthcare issues for the 2023 Texas Legislative Session - including healthcare costs and potential reforms to the system, access to care, and public health.

**January 25, 2023**

[Learn more here](#)



LAUNCHBIO

### MRL Ventures Fund *LaunchBio*

Join LaunchBio and MRL Ventures to participate in a 1 minute pitch and a Q&A with investors, apply before **January 20, 2023** to be considered.

**January 26, 2023**

[Learn more here](#)



TEXAS TECH UNIVERSITY  
Innovation Hub  
at Research Park

### Want to Accelerate Your Startup & Win \$25,000?

*TTU Innovation Hub*

Join the Texas Tech Innovation Hub for their seminar on how you can accelerate your startup and win \$25,000!

**February 1, 2023**

[Learn more here](#)



**Meet MassChallenge Dallas**  
*MassChallenge*

Join MassChallenge to meet their team in Dallas and learn about the upcoming the 2023 US early stage program.

**February 2, 2023**

[Learn more here](#)

*BioNTX works to build a strong bioscience and healthcare innovation community through collaborative peer to peer networking events and educational programming.*

[Let us know about your event!](#)

[View the North Texas community calendar of events](#)

[Look at upcoming BioNTX events](#)



## Join BioNTX

BioNTX delivers opportunities for Members to connect across the State. Join us and collaborate with others, receive industry insights and visibility. We serve as the voice and champion for the life science community in NTX.



**January 20, 2023**

<http://www.BioNTX.org> | 5000 Riverside Drive, Building 6, Suite 100E, Irving, TX 75039

[Unsubscribe kotto@biontx.org](mailto:kotto@biontx.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by [kotto@biontx.org](mailto:kotto@biontx.org)

